Table III.

Comparison of immunohistochemical marker expression in previous studies and the present study.

First author (year)	Country	Cases, no.	CD10, n (%)	BCL-6, n (%)	MUM-1, n (%)	BCL-2, n (%)	Algorithm	GCB, n (%)	Non-GCB, n (%)	(Refs.)
Mahadevan et al (2015)	India	24	0	12/24 (50.0)	22/24 (91.7)	–	Hans and Chang	–	22/24 (91.7)	(14)
Aki et al (2013)	Turkey	35	6/35 (17.1)	15/35 (42.8)	27/35 (77.1)	15/35 (42.8)	Hans	6/35 (17.1)	29/35 (82.9)	(15)
Hattab et al (2010)	USA	31	4/31 (12.9)	26/31 (83.9)	27/31 (87.1)	21/30 (70.0)	Hans	5/31 (16.1)	26/31 (83.9)	(16)
Raoux et al (2010)	France	39	8/39 (20.5)	14/39 (35.9)	23/39 (60.0)	33/39 (84.6)	Hans	13/39 (25.7)	26/39 (74.3)	(17)
Momota et al (2010)	Japan	27	6/27 (22.2)	13/27 (48.1)	22/27 (81.5)	–	Hans and Chang	1/23 (4.4)	22/23 (95.6)	(18)
Kinoshita et al (2010)	Japan	32	6/32 (18.8)	21/32 (65.6)	27/32 (84.4)	–	Hans and Chang	8/29 (27.6)	21/29 (72.4)	(19)
Bhagavathi et al (2008)	USA	21	1/21 (4.8)	19/21 (90.5)	19/21 (90.5)	17/21 (81.0)	Hans	2/21 (9.5)	19/21 (90.5)	(20)
Levy et al (2008)	USA	38	3/38 (7.9)	18/38 (47.4)	36/38 (94.7)	–	Hans	5/38 (13.0)	33/38 (87.0)	(21)
Cheng et al (2008)	China	47	3/47 (6.4)	25/47 (53.2)	43/47 (91.5)	–	Chang	4/47 (8.5)	43/47 (91.5)	(22)
Lin et al (2006)	Taiwan	51	9/51 (17.6)	30/51 (58.9)	43/51 (84.3)	25/51 (49.0)	Hans	11/51 (21.6)	40/51 (78.4)	(23)
Camilleri-Broët et al (2006)	France	82	2/82 (2.4)	45/81 (55.5)	75/81 (92.6)	45/81 (55.5)	Hans and Chang	3/82 (3.7)	79/82 (96.3)	(24)
Present study	China	89	15/89 (16.9)	46/89 (51.7)	82/89 (92.1)	63/86 (73.3)	Hans and Chang	18/89 (20.2)	71/89 (80.9)

CD10, cluster of differentiation 10; BCL, B cell lymphoma; MUM-1, multiple myeloma-1; GCN, germinal center B cell-like.